zyne stock price

What is the upside for zynerba pharmaceuticals (Zyn) stock?

Their forecasts range from $7.25 to $18.00. On average, they anticipate Zynerba Pharmaceuticals' share price to reach $10.56 in the next twelve months. This suggests a possible upside of 229.0% from the stock's current price. View analysts' price targets for Zynerba Pharmaceuticals or view top-rated stocks among Wall Street analysts.

What are analysts'target prices for zynerba Pharmaceuticals'stock?

7 brokers have issued 1-year target prices for Zynerba Pharmaceuticals' stock. Their predictions range from $11.00 to $36.00. On average, they anticipate Zynerba Pharmaceuticals' share price to reach $22.00 in the next year.

How much is a share of zynerba worth?

One share of ZYNE stock can currently be purchased for approximately $3.21. How much money does Zynerba Pharmaceuticals make? Zynerba Pharmaceuticals has a market capitalization of $132.31 million and generates $90 thousand in revenue each year.

Does Zyne stock pay dividends?

Restricted stock typically is that issued to company insiders with limits on when it may be traded. A company's dividend expressed as a percentage of its current stock price. ZYNE is not currently paying a regular dividend. The total number of shares of a security that have been sold short and not yet repurchased.

Is ZYNE stock a good buy?

The consensus among 1 Wall Street analyst covering (NASDAQ: ZYNE) stock is to Strong Buy ZYNE stock.

Will Zynerba Pharmaceuticals Stock go up?

The 4 analysts offering 12-month price forecasts for Zynerba Pharmaceuticals Inc have a median target of 7.00, with a high estimate of 11.00 and a low estimate of 1.00. The median estimate represents a +508.70% increase from the last price of 1.15.

What is ZYNE Pharmaceuticals?

Zynerba Pharmaceuticals, Inc. is primarily engaged in the pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, including Fragile X syndrome (FXS), autism spectrum disorder (ASD), and 22q11. 2 deletion syndrome (22q).

What company is ZYNE?

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company develops next-generation synthetic cannabinoid therapeutics for transdermal delivery for patients with significant unmet medical needs.

What happened to corbus pharmaceuticals?

Corbus Pharmaceuticals' (Nasdaq: CRBP) shares have dropped precipitously on the news that its drug lenabasum has failed to effectively treat the inflammatory disease dermatomyositis in a late-stage clinical trial.

Should I buy or sell Zynerba Pharmaceuticals stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zynerba Pharmaceuticals in the last twelve months. There are curr...

What is Zynerba Pharmaceuticals' stock price forecast for 2022?

2 analysts have issued twelve-month price objectives for Zynerba Pharmaceuticals' shares. Their forecasts range from $9.00 to $9.00. On average, th...

How has Zynerba Pharmaceuticals' stock price performed in 2022?

Zynerba Pharmaceuticals' stock was trading at $2.88 on January 1st, 2022. Since then, ZYNE shares have decreased by 63.2% and is now trading at $1....

When is Zynerba Pharmaceuticals' next earnings date?

Zynerba Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast fo...

How were Zynerba Pharmaceuticals' earnings last quarter?

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) issued its earnings results on Monday, May, 16th. The company reported ($0.21) EPS for the quarter, top...

Who are Zynerba Pharmaceuticals' key executives?

Zynerba Pharmaceuticals' management team includes the following people: Mr. Armando Anido MBA , Chairman & CEO (Age 64, Pay $993.36k) Ms. Terri...

Who are some of Zynerba Pharmaceuticals' key competitors?

Some companies that are related to Zynerba Pharmaceuticals include Alaunos Therapeutics (TCRT) , Matinas BioPharma (MTNB) , ProPhase Labs (PRPH)...

What other stocks do shareholders of Zynerba Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zynerba Pharmaceuticals investors own include (CGC) , Ca...

When did Zynerba Pharmaceuticals IPO?

(ZYNE) raised $42 million in an IPO on Wednesday, August 5th 2015. The company issued 3,000,000 shares at $13.00-$15.00 per share. Jefferies and Pi...

About Zynerba Pharmaceuticals

Headlines

Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on research and development of rare and near-rare neuropsychiatric conditions. The firm offers Zygel product, which formulated as a permeation-enhanced gel for transdermal delivery. The company was founded by Audra L.

Is Medical Marijuana Really A Slippery Slope? CVSI Distribution Agreement with GNC

Zynerba announces clinical updates for Fragile X and 22q11.2...Zynerba announces clinical updates for Fragile X and 22q11.2...

The Daily Biotech Pulse: Pfizer-BioNTech Partner For Shingles Vaccine, Annexon Huntington Disease Study Disappoints, Amneal Buys Neurology Assets

The Best Daily Overview Of The Cannabis Space CV Sciences Announces New Distribution Agreement with GNC. $CVSI Massachusetts cannabis prices continue to fall Kentucky GOP Sen. Damon Thayer: "Medical cannabis is a slippery slope for recreational marijuana.”

Signals & Forecast

Here's a roundup of top developments in the biotech space over the last 24 hours.

Support, Risk & Stop-loss

A buy signal was issued from a pivot bottom point on Friday, January 21, 2022, and so far it has risen 4.64%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD).

Is Zynerba Pharmaceuticals stock A Buy?

Zynerba Pharmaceuticals finds support from accumulated volume at $2.45 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

Insiders are very negative

Zynerba Pharmaceuticals holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

About Zynerba Pharmaceuticals

In the last 1 trades there were . The last trade was done 19 046 days ago by who bough 0 shares.

Golden Star Signal

Zynerba Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery.

Top Fintech Company

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!